Tumor markers and colorectal cancer: Utility in management
- 24 November 2003
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 84 (4), 239-248
- https://doi.org/10.1002/jso.10325
Abstract
Colorectal cancer (CRC) is a leading cause of morbidity and mortality. Although genetic testing can screen for rare hereditary CRC syndromes, there is no ideal means of screening for sporadic forms of CRC. This review will focus on markers that are currently used in the management of sporadic CRC and their limitations, as well as possible future clinical applications. J. Surg. Oncol. 2003;84:239–248.Keywords
This publication has 50 references indexed in Scilit:
- Current and Evolving Strategies for Colorectal Cancer ScreeningCancer Control, 2003
- Molecular and biochemical markers in colorectal cancerAnnals Of Oncology, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- What’s New with Tumor Markers for Colorectal Cancer?Digestive Surgery, 2000
- Matrix metalloproteinase inhibitors: A novel class of anticancer agentsAdvances in Enzyme Regulation, 1995
- Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressivenessHuman Pathology, 1995
- Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomasCancer, 1995
- Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon diseaseJournal of Clinical Laboratory Analysis, 1995
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988
- PHYSICOCHEMICAL AND IMMUNOCHEMICAL PROPERTIES OF CARCINOEMBRYONIC ANTIGEN (CEA) FROM DIFFERENT TUMOUR SOURCESImmunology & Cell Biology, 1978